AERI - Aerie Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
56.55
+0.40 (+0.71%)
At close: 4:00PM EDT

56.55 0.00 (0.00%)
After hours: 4:50PM EDT

Stock chart is not supported by your current browser
Previous Close56.15
Open56.20
Bid46.15 x 2900
Ask62.50 x 1300
Day's Range56.05 - 57.40
52 Week Range47.05 - 74.75
Volume338,038
Avg. Volume401,579
Market Cap2.557B
Beta0.50
PE Ratio (TTM)N/A
EPS (TTM)-4.96
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est85.22
Trade prices are not sourced from all markets
  • See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
    Markit4 days ago

    See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.

    Short interest is moderate for AERI with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.

  • Business Wire6 days ago

    Aerie Pharmaceuticals to Present at Ophthalmology Futures Forums in Vienna, Austria

    Aerie Pharmaceuticals, Inc. , an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced that Richard Rubino, Chief Financial Officer, will present at the Ophthalmology Futures European Forum held prior to the 36th Congress ...

  • Business Wire6 days ago

    Aerie Pharmaceuticals Appoints David W. Gryska to the Company’s Board of Directors

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced that David W. Gryska has been appointed to the Company’s Board of Directors and will also be a member of the Audit Committee of the Board. Mr. Gryska recently announced his planned retirement at the end of 2018 as the Chief Financial Officer and Executive Vice President of Incyte Corp., and is currently on the boards of Seattle Genetics, Inc. and PDL BioPharma, Inc. Previously, he held the position of President, CEO, COO and Director at Myrexis, Inc., Chief Financial Officer and Senior Vice President at Celgene Corp., and Chief Financial Officer and Senior Vice President at Scios, Inc. Mr. Gryska has spent over 20 years as a senior executive at life science and biotechnology companies with extensive experience relating to financings, acquisitions, global expansion and strategic transactions.

  • ACCESSWIRE7 days ago

    Today's Research Reports on Trending Tickers: Momenta Pharmaceuticals and Aerie Pharmaceuticals

    The Dow Jones Industrial Average climbed 0.44 percent to close at 25,971.06, while the S&P 500 Index increased 0.37 percent to close at 2,887.89. The Nasdaq Composite Index gained 0.61 percent to close at 7,972.47.

  • Business Wire7 days ago

    Aerie Pharmaceuticals Announces Appointment of Robert Finan as Director of Finance

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced the appointment of Robert Finan, Director of Finance, reporting to Christopher Staten, Vice President of Finance. Mr. Finan will lead Aerie’s finance, operations and strategy activities for Aerie’s manufacturing plant in Athlone, Ireland. Mr. Finan most recently held a related position at Sanofi Genzyme Ireland.

  • Business Wire9 days ago

    Aerie Pharmaceuticals Announces Appointment of Thomas A. Shepard as Vice President, Implant Manufacturing

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced the appointment of Thomas A. Shepard as Vice President, Implant Manufacturing, reporting to Casey Kopczynski, Ph.D., Aerie’s Chief Scientific Officer. Mr. Shepard will lead Aerie’s implant manufacturing facility in Durham, North Carolina, including responsibility for the development, manufacture and global supply of Aerie’s ophthalmic drug-eluting implants. Mr. Shepard most recently held a related position at Pfizer, Inc.

  • Why Is Aerie (AERI) Down 10.6% Since Last Earnings Report?
    Zacks11 days ago

    Why Is Aerie (AERI) Down 10.6% Since Last Earnings Report?

    Aerie (AERI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • GlobeNewswire14 days ago

    Factors of Influence in 2018, Key Indicators and Opportunity within Aerie Pharmaceuticals, BioScrip, Celsion, Primoris Services, Cyclacel Pharmaceuticals, and Barnes Group — New Research Emphasizes Economic Growth

    NEW YORK, Sept. 05, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • ACCESSWIRE21 days ago

    Today's Research Reports on Trending Tickers: Aerie Pharmaceuticals, Inc. and Array BioPharma Inc.

    NEW YORK, NY / ACCESSWIRE / August 29, 2018 / U.S. equities rallied on Tuesday as consumer confidence hits an eighteen-year high and optimism over new proposed trade agreement between U.S. and Mexico continue ...

  • See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
    Markit22 days ago

    See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.

    Short interest is moderate for AERI with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.

  • Thomson Reuters StreetEvents24 days ago

    Edited Transcript of AERI earnings conference call or presentation 8-Aug-18 9:00pm GMT

    Q2 2018 Aerie Pharmaceuticals Inc Earnings Call

  • EXCLUSIVE: Aerie's drive to change the world of eye care
    American City Business Journals26 days ago

    EXCLUSIVE: Aerie's drive to change the world of eye care

    Driving a drug company from concept to commercialization is never easy, and can require astonishing amounts of cash. One company hitting its stride is Aerie Pharmaceuticals, founded in 2005. How did Aerie get started?

  • Business Wirelast month

    Aerie Pharmaceuticals Announces Appointment of Jeffrey White, Ph.D. as Director, Toxicology and Pharmacokinetics

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced the appointment of Jeffrey White, Ph.D. as Director, Toxicology and Pharmacokinetics, reporting to Eric Carlson, Ph.D., Aerie’s Vice President of Research and Development. Dr. White will have operational and scientific responsibility for Aerie’s nonclinical development function, including safety, toxicology and pharmacokinetics studies.

  • Array BioPharma Posted Net Loss of $52.4 Million in Q4
    Market Realistlast month

    Array BioPharma Posted Net Loss of $52.4 Million in Q4

    On August 14, Array BioPharma (ARRY) announced its fourth quarter and full fiscal 2018 results for the period ended June 30, 2018. The adjusted EPS (earnings per share) for the fourth quarter came in at -$0.17, exceeding analysts’ estimate of -$0.21. Net loss in the fourth quarter of fiscal 2018 was $52.4 million as compared to $29.6 million losses reported in the fourth quarter of fiscal 2017.

  • What Analysts Recommend for Array BioPharma Stock
    Market Realistlast month

    What Analysts Recommend for Array BioPharma Stock

    Array BioPharma (ARRY) announced its fourth-quarter and full fiscal 2018 results on August 14. That day, ARRY stock registered a decline of ~2.6% and fell further the following day. The decline in stock prices was triggered by the negative investor sentiments due to the Array BioPharma’s fourth-quarter results falling short of estimates. In this article, we’ll look at analysts’ latest recommendations and target prices on ARRY stock over the next 12 months.

  • GlobeNewswirelast month

    Factors of Influence in 2018, Key Indicators and Opportunity within inTest, Hooker Furniture, American Public Education, Gevo, Envestnet, and Aerie Pharmaceuticals — New Research Emphasizes Economic Growth

    NEW YORK, Aug. 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of inTest ...

  • Durham firm gets encouraging news on glaucoma treatment
    American City Business Journalslast month

    Durham firm gets encouraging news on glaucoma treatment

    A Durham company focused on developing therapies for people with eye diseases received some encouraging news on a key drug designed to treat glaucoma patients. Aerie Pharmaceuticals (NASDAQ:AERI) announced Wednesday that its Rhopressa product, which is taken as an eye drop, had strong top-line efficacy results in a study involving open-angle glaucoma. Open-angle glaucoma is one of the main forms of glaucoma, which is a leading cause of blindness.

  • Business Wirelast month

    Aerie Pharmaceuticals Reports Topline Result from Rhopressa® Mechanism of Action Study

    NCT03233308) designed to evaluate the effect of Rhopressa® (netarsudil ophthalmic solution) 0.02% on aqueous humor dynamics in patients with open-angle glaucoma or ocular hypertension. While several pre-clinical models and a previous study in healthy volunteers examined the effect of Rhopressa® on trabecular meshwork outflow facility, this study is the first performed on glaucoma patients to confirm that it lowers intraocular pressure (IOP) primarily through this mechanism.

  • See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.

    Aerie Pharmaceuticals Inc NASDAQ NMS:AERI

  • Aerie (AERI) Earnings Miss in Q2, Rhopressa Performs Well
    Zackslast month

    Aerie (AERI) Earnings Miss in Q2, Rhopressa Performs Well

    Aerie's (AERI) Q2 loss is wider than expected on account of higher expenses. Nevertheless, Rhopressa's sales beat estimates as demand picks up.

  • Has Aerie Pharmaceuticals (AERI) Outpaced Other Medical Stocks This Year?
    Zackslast month

    Has Aerie Pharmaceuticals (AERI) Outpaced Other Medical Stocks This Year?

    Is (AERI) Outperforming Other Medical Stocks This Year?

  • Why this Durham company can be $20M to $30M richer
    American City Business Journalslast month

    Why this Durham company can be $20M to $30M richer

    Durham-based Aerie Pharmaceuticals (Nasdaq: AERI) is expecting between $20 million and $30 million this year from its first drug approved by the U.S. Food and Drug Administration. Aerie’s first glaucoma drug Rhopressa just saw its commercial launch in the U.S. on April 30, with net revenues of $2.4 million in the second quarter, the company reported Wednesday afternoon.

  • Aerie Pharmaceuticals (AERI) Reports Q2 Loss, Tops Revenue Estimates
    Zackslast month

    Aerie Pharmaceuticals (AERI) Reports Q2 Loss, Tops Revenue Estimates

    Aerie (AERI) delivered earnings and revenue surprises of -11.76% and 108.88%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Aerie: 2Q Earnings Snapshot

    The North Carolina, North Carolina-based company said it had a loss of $1.40 per share. Losses, adjusted for stock option expense, came to $1.14 per share. The results did not meet Wall Street expectations. ...

  • Business Wirelast month

    Aerie Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update

    Conference Call and Webcast Today, August 8th, at 5:00 p.m. ET